Results 81 to 90 of about 31,793 (243)

Frequency of dyspnea related to intake of ticagrelor or clopidogrel in patients with chronic coronary syndrome undergoing coronary intervention

Кардиоваскулярная терапия и профилактика
In patients with chronic coronary syndrome, ticagrelor decreases cardiovascular events more efficiently than clopidogrel. In several studies investigating novel P2Y12 inhibitors dyspnea has been detected.
Dunya Habeeb Shnain, Ghassan Mohammed Mahmood, Sara Omar Ahmed   +2 more
doaj   +1 more source

Long non‐coding RNA lncAPAT promotes atherosclerotic plaque instability by targeting ribosomal protein L22

Clinical and Translational Medicine, Volume 16, Issue 1, January 2026.
LncAPAT interacted with the promoter region of RPL22 to inhibit RPL22 transcriptional activity and increase the expression of MCP‐1, thereby contributing to plaque instability. Abstract Background Long non‐coding RNAs (lncRNAs) regulate macrophage inflammation and atherosclerotic plaque stability, but mechanisms need comprehensive investigations ...
Rongxia Li, Qiyue Zhang, Yu Chen, Shuting Wang, Shuang Han, Adalaiti Kamili, Yixuan Zhong, Shujun Yang, Weili Zhang   +8 more
wiley   +1 more source

Comparison of P2Y12 inhibitors for mortality and stent thrombosis in patients with acute coronary syndromes: Single center study of 10 793 consecutive ‘real-world’ patients

Platelets, 2017
Three oral platelet P2Y12 inhibitors, clopidogrel, prasugrel, and ticagrelor, are available for reducing the risk of cardiovascular death and stent thrombosis in patients with acute coronary syndromes (ACS).
Rebecca Gosling, Momina Yazdani, Yasir Parviz, Ian R Hall, Ever D. Grech, Julian P Gunn, Robert F. Storey, Javaid Iqbal   +7 more
doaj   +1 more source

Association of the Geriatric Nutritional Risk Index With Prognosis in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention

Immunity, Inflammation and Disease, Volume 14, Issue 1, January 2026.
ABSTRACT Background and Aims The geriatric nutritional risk index (GNRI) has shown good predictive value for some diseases. However, its association with major adverse cardiovascular events (MACEs) in acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI) remains uncertain.
Yuewen Qi, Xinchen Wang, Yan Liu, Ying Zhang, Qiyu Sun, Chen Wei, Ge Song, Jingyi Liu, Fei Shi, Lixian Sun   +9 more
wiley   +1 more source

Stability of Medications Administered via Enteral Feeding Tubes: A Systematic Review

Clinical and Translational Science, Volume 19, Issue 1, January 2026.
The graphical abstract for the stability of medicatioins administred via enteral feeding tube: A systematic review ((PROSPERO, registration number: CRD42024580820)). ABSTRACT Feeding tubes are essential for patients unable to maintain adequate oral intake, serving multiple purposes including nutrition delivery and medication administration.
Lena Alodat, Wejdan Shahin, Lina Breik, Ayman Allahham   +3 more
wiley   +1 more source

Critical appraisal of ticagrelor in the management of acute coronary syndrome

Therapeutics and Clinical Risk Management, 2011
James J Nawarskas, Stanley S SnowdenUniversity of New Mexico College of Pharmacy, Albuquerque, NM, USAAbstract: Ticagrelor is a novel P2Y12 receptor antagonist which, like clopidogrel and prasugrel, functions by blocking adenosine diphosphate-mediated ...
Nawarskas JJ, Snowden SS
doaj  

Implications of inflammation and sex in lower extremity arterial disease

European Journal of Clinical Investigation, Volume 56, Issue 1, January 2026.
The graphical abstract illustrates the role of inflammation and sex‐related differences in lower extremity artery disease (LEAD). Key inflammatory biomarkers associated with LEAD include C‐reactive protein (CRP), fibrinogen, interleukin‐6 (IL‐6), and D‐dimer, which contribute to vascular inflammation and atherosclerotic plaque formation in lower limb ...
Katja Schnidrig, Manovriti Thakur, Aleksandra Tuleja, Sarah Maike Bernhard, Heidi Noels, Drosos Kotelis, Marc Schindewolf, Yvonne Döring   +7 more
wiley   +1 more source

Cost-effectiveness of genotype-guided and dual antiplatelet therapies in acute coronary syndrome. [PDF]

, 2014
BackgroundThe choice of antiplatelet therapy after acute coronary syndrome (ACS) is complicated: Ticagrelor and prasugrel are novel alternatives to clopidogrel, patients with some genotypes may not respond to clopidogrel, and low-cost generic ...
Boothroyd, Derek B, Dudley, R Adams, Garber, Alan M, Hlatky, Mark A, Kazi, Dhruv S, Mell, Matthew W, Moshkevich, Solomon, Owens, Douglas K, Rhee, Ceron, Shah, Rashmee U   +9 more
core   +1 more source

Anticoagulant or Antithrombotic Therapy After Early Neurological Deterioration in Patients With Branch Atheromatous Disease Receiving Dual Antiplatelet Therapy

International Journal of Clinical Practice, Volume 2026, Issue 1, 2026.
Objective We evaluated the effectiveness and safety of adding tirofiban or argatroban after early neurological deterioration (END) in patients with branch atheromatous disease (BAD) receiving dual antiplatelet therapy and compared the outcomes with those of patients who continued dual antiplatelet therapy alone. Methods This retrospective study focused
Xuemin Zhong, Juan Yang, Ronghua Xu, Jian Wang, Nikhat Kaura   +4 more
wiley   +1 more source

Prolonged dual anti-platelet therapy in stable coronary disease: a comparative observational study of benefits and harms in unselected versus trial populations [PDF]

, 2016
Objective: To estimate the potential magnitude in unselected patients of the benefits and harms of prolonged dual antiplatelet therapy after acute myocardial infarction seen in selected patients with high risk characteristics in trials.
Chung, SC, Denaxas, S, Emmas, C, Hemmingway, H, Moayyeri, A, Pasea, L, Pujades Rodriguez, MDM, Rapsomaniki, E, Shah, AD, Stogiannis, D, Timmis, A   +10 more
core   +2 more sources